Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thiazolidinediones

R R Henry1

  • 1Division of Endocrinology and Metabolism, University of California, San Diego, USA.

Endocrinology and Metabolism Clinics of North America
|October 6, 1997
PubMed
Summary
This summary is machine-generated.

Thiazolidinediones, like troglitazone, improve insulin sensitivity and reduce blood sugar in type II diabetes. This class of drugs also shows promise for treating other metabolic conditions and preventing diabetes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.

Diabetes & metabolism·2017
Same author

Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.

Diabetes, obesity & metabolism·2016
Same author

Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes.

Diabetes, obesity & metabolism·2015
Same author

Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials.

Diabetes, obesity & metabolism·2015
Same author

Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study.

Diabetes, obesity & metabolism·2013
Same author

Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial.

Diabetes, obesity & metabolism·2013
Same journal

Navigating Adrenal Disease: A Comprehensive, Practical Guide for the Clinician.

Endocrinology and metabolism clinics of North America·2026
Same journal

Adrenal Disorders in Pregnancy.

Endocrinology and metabolism clinics of North America·2026
Same journal

Diagnosis and Management of Adrenocortical Carcinoma.

Endocrinology and metabolism clinics of North America·2026
Same journal

Pheochromocytomas and Paragangliomas.

Endocrinology and metabolism clinics of North America·2026
Same journal

Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

Endocrinology and metabolism clinics of North America·2026
Same journal

Primary Bilateral Macronodular Adrenal Hyperplasia.

Endocrinology and metabolism clinics of North America·2026
See all related articles

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Insulin resistance is a core feature of type II diabetes and related metabolic disorders.
  • Thiazolidinediones represent a novel therapeutic class targeting insulin resistance mechanisms.
  • Troglitazone is the first approved thiazolidinedione for human use.

Purpose of the Study:

  • To review the therapeutic potential of thiazolidinediones, specifically troglitazone.
  • To highlight troglitazone's efficacy in managing type II diabetes and the insulin resistance syndrome.
  • To discuss troglitazone's mechanism of action and unique clinical advantages.

Main Methods:

  • Review of existing literature on thiazolidinediones and troglitazone.
  • Analysis of troglitazone's pharmacological properties and clinical trial data.

Related Experiment Videos

  • Discussion of peroxisome proliferator-activated receptors (PPARs) activation.

    • Main Results:

    • Thiazolidinediones improve insulin action and reduce hyperinsulinemia.
    • Troglitazone effectively lowers glycemia and insulin needs in type II diabetes.
    • Troglitazone also improves dyslipidemia, hypertension, and cardiovascular disease risk.

    Conclusions:

    • Thiazolidinediones, exemplified by troglitazone, offer a significant advancement in managing type II diabetes.
    • Troglitazone's benefits extend to other components of the insulin resistance syndrome.
    • These compounds hold promise for diabetes prevention and treating other insulin-resistant states like polycystic ovary disease.